The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).

Topic PTSD
Compound Psilocybin
Status Recruiting
Results Published
Start date 11 April 2022
End date 21 August 2023
Chance of happening 89%
Phase Phase II
Design Open
Type Interventional
Generation Second
Participants 29
Sex All
Age 18- 99
Therapy No

Trial Details

The safety and tolerability of COMP360 in participants with post-traumatic stress disorder (PTSD).

NCT Number NCT05312151

Sponsors & Collaborators

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.

King's College London
The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is one of Europe's top centres for mental health and related neurosciences research.

Measures Used

Clinician-Administered PTSD Scale for DSM-5
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is often considered the gold standard in PTSD assessment. The 30-item structured interview was developed by staff at the U.S. Department of Veterans Affairs National Centre for PTSD. CAPS can be used to make a current diagnosis, lifetime diagnosis or assess PTSD symptoms over the past week in accordance with DSM-5 criteria.

Data attribution

A large set of the trials in our database are sourced from (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.